Showing results (11-20 of 16) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Pancreatic Cancer|March 29, 2020
Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid TumorsMark H O'Hara, Wells Messersmith, Hedy Kindler, et al.Frontiers in Oncology|October 16, 2018
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaPrajwal Boddu, Gautam Borthakur, Mythili Koneru, et al.Cancer Medicine|July 28, 2025
Real-World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1-3 Prior Lines of Therapy: Optum DatabaseBinod Dhakal, Hermann Einsele, Jordan M Schecter, et al.The Lancet. Oncology|January 10, 2026
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trialHermann Einsele, Jesús San-Miguel, Binod Dhakal, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2025
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple MyelomaSundar Jagannath, Thomas G Martin, Yi Lin, et al.Clinical Lymphoma, Myeloma & Leukemia|May 20, 2026
Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE StudiesPaula Rodríguez-Otero, Jaime Gállego Pérez-Larraya, Yi Lin, et al.Pageof 2